<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<?properties manuscript?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-journal-id">8606714</journal-id>
<journal-id journal-id-type="pubmed-jr-id">4754</journal-id>
<journal-id journal-id-type="nlm-ta">J Child Neurol</journal-id>
<journal-id journal-id-type="iso-abbrev">J. Child Neurol.</journal-id>
<journal-title-group>
<journal-title>Journal of child neurology</journal-title>
</journal-title-group>
<issn pub-type="ppub">0883-0738</issn>
<issn pub-type="epub">1708-8283</issn>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">29246098</article-id>
<article-id pub-id-type="pmc">5739070</article-id>
<article-id pub-id-type="doi">10.1177/0883073817739509</article-id>
<article-id pub-id-type="manuscript">NIHMS911839</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Optic Pathway Gliomas in Neurofibromatosis Type 1</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Campen</surname>
<given-names>Cynthia J.</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Gutmann</surname>
<given-names>David H.</given-names>
</name>
<degrees>MD, PhD</degrees>
<xref ref-type="aff" rid="A2">2</xref>
</contrib>
</contrib-group>
<aff id="A1">
<label>1</label>Department of Neurology, Stanford University, Palo Alto CA</aff>
<aff id="A2">
<label>2</label>Department of Neurology, Washington University School of Medicine, St. Louis MO</aff>
<author-notes>
<corresp id="FN1">Address correspondence to: David H. Gutmann, MD, PhD, Department of Neurology, Washington University School of Medicine, Box 8111, 660 South Euclid Avenue, St. Louis, MO 63110. 314-362-7379 (phone); <email>gutmannd@wustl.edu</email></corresp>
<fn fn-type="COI-statement" id="FN2">
<p><bold>Conflicts</bold>: None to disclose.</p>
</fn>
</author-notes>
<pub-date pub-type="nihms-submitted">
<day>10</day>
<month>10</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="ppub">
<month>1</month>
<year>2018</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>01</day>
<month>1</month>
<year>2019</year>
</pub-date>
<volume>33</volume>
<issue>1</issue>
<fpage>73</fpage>
<lpage>81</lpage>
<!--elocation-id from pubmed: 10.1177/0883073817739509-->
<abstract>
<p id="P1">Neurofibromatosis type 1 (NF1) is one of the most common brain tumor predisposition syndromes, in which affected children are prone to develop low-grade gliomas. While NF1-associated gliomas can be found in several brain regions, the majority arise in the optic nerves, chiasm, tracks, and radiations (optic pathway gliomas; OPGs). Owing to their location, 35â€“50% of affected children present with reduced visual acuity. Unfortunately, despite tumor stabilization following chemotherapy, most children have improved vision. For this reasons, more effective therapies are being sought that reflect a deeper understanding of the <italic>NF1</italic> gene and the use of authenticated <italic>Nf1</italic> genetically-engineered mouse strains. The implementation of these models for drug discovery and validation has galvanized molecularly-targeted clinical trials in children with NF1-OPG. Future research focused on defining the cellular and molecular factors that underlie optic glioma development and progression also has the potential to provide personalized risk assessment strategies for this pediatric population.</p>
</abstract>
<kwd-group>
<kwd>astrocytoma</kwd>
<kwd>pilocytic</kwd>
<kwd>precision medicine</kwd>
<kwd>RAS</kwd>
<kwd>vision</kwd>
<kwd>low-grade glioma</kwd>
</kwd-group>
</article-meta>
</front>
</article>
</pmc-articleset>